Arca
Skip to content
Tools
Tools

NDA 218879: Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See NDA 218879's history or OWP Pharmaceuticals's company page.

On Jan 3, 2025, FDA declined to approve NDA 218879 (NDA 218879) from OWP Pharmaceuticals, Inc. in its present form, citing product quality, facility inspections. openFDA lists it as not yet approved.

  • Letter date: Jan 3, 2025
  • Application: NDA 218879
  • Since then: Not approved

What FDA Cited

FDA's own section headings in the letter; each finds other letters citing it

Product qualityFacility inspections

The Letter

Text from openFDA; FDA's scanned original (PDF) โ†—

Dear Paul Sudhakar: Please refer to your new drug application for (lamotrigine) oral suspension. We also acknowledge receipt of your amendment dated we. which was not reviewed for this action. You may incorporate applicable sections of the amendment by specific reference as part of your response to the deficiencies cited in this letter. We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues.

PRODUCT QUALITY

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

PRESCRIBING INFORMATION

We reserve comment on the proposed labeling until the application is otherwise adequate. We encourage you to review the labeling review resources on the Prescription Drug Labeling Resources! and Pregnancy and Lactation Labeling Final Rule? websites, including regulations and related guidance documents and the Selected Requirements for Prescribing Information (SRPI) - a checklist of important format items from labeling regulations and guidances.

If you revise labeling, use the SRPI checklist to ensure that the Prescribing Information conforms with format items in regulations and guidances. Your response must include updated content of labeling [21 CFR 314.50(I)(1)(i)] in structured product labeling (SPL) format as described at FDA.gov.ยฐ

CARTON AND CONTAINER LABELING

1 2

3

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

The following are draft carton and container labeling comments which should be addressed in any subsequent resubmission:

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

FACILITY INSPECTIONS

The drug substance manufacturing facili , Proposed to support the application is not operational. A satisfactory inspection may be required before this application may be approved. As part of your full response to this Complete Response letter, confirm that this facility is ready for inspection. Note that the application cannot be approved if any proposed facility for the commercial manufacturing is not acceptable for the proposed function on the action date.

PROPRIETARY NAME

Refer to correspondence dated, which addresses the proposed proprietary name, . This name was found conditionally acceptable pending approval of the application in the current review cycle. Resubmit the proposed proprietary name when you respond to all of the application deficiencies that have been identified in this letter.

SAFETY UPDATE

When you respond to the above deficiencies, include a safety update as described at 21 CFR 314.50(d)(5)(vi)(b). The safety update should include data from all nonclinical

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov and clinical studies/trials of the drug under consideration regardless of indication, dosage form, or dose level.

(1) Describe in detail any significant changes or findings in the safety profile.

(2) When assembling the sections describing discontinuations due to adverse events, serious adverse events, and common adverse events, incorporate new safety data as follows:

e Present new safety data from the studies/clinical trials for the proposed indication using the same format as in the original submission.

e Present tabulations of the new safety data combined with the original application data.

e Include tables that compare frequencies of adverse events in the original application with the retabulated frequencies described in the bullet above.

e For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in Clinical trials.

(3) Present a retabulation of the reasons for premature trial discontinuation by incorporating the dropouts from the newly completed trials. Describe any new trends or patterns identified.

(4) Provide case report forms and narrative summaries for each subject who died during a Clinical trial or who did not complete a trial because of an adverse event. In addition, provide narrative summaries for serious adverse events.

(5) Describe any information that suggests a substantial change in the incidence of common, but less serious, adverse events between the new data and the original application data.

(6) Provide updated exposure information for the clinical studies/trials (e.g., number of subjects, person time).

(7) Provide a summary of worldwide experience on the safety of this drug. Include an updated estimate of use for drug marketed in other countries.

(8) Provide English translations of current approved foreign labeling not previously submitted.

OTHER

Within one year after the date of this letter, you are required to resubmit or take other actions available under 21 CFR 314.110. If you do not take one of these actions, we

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov may consider your lack of response a request to withdraw the application under 21 CFR 314.65. You may also request an extension of time in which to resubmit the application.

A resubmission must fully address all the deficiencies listed in this letter and should be clearly marked with "RESUBMISSION" in large font, bolded type at the beginning of the cover letter of the submission. The cover letter should clearly state that you consider this resubmission a complete response to the deficiencies outlined in this letter. A partial response to this letter will not be processed as a resubmission and will not start a new review cycle.

You may request a meeting or teleconference with us to discuss what steps you need to take before the application may be approved. If you wish to have such a meeting, submit your meeting request as described in the draft guidance for industry Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products.

The product may not be legally marketed until you have been notified in writing that this application is approved.

If you have any questions, contact oe

Sincerely,

{See appended electronic signature page} (b) (4)

U.S. Food and Drug Administration Silver Spring, MD 20993 www.fda.gov

Signature Page 1 of 1

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

(b) (4)

01/03/2025 10:11:55 AM

Record

Company
OWP Pharmaceuticals, Inc.
Application
NDA 218879
Status in openFDA
Unapproved

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.